AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am. J. Trop. Med. Hyg., 71(6), 2004, pp. 715-722
Copyright © 2004 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KACHUR, S. P.
Right arrow Articles by BLOLAND, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KACHUR, S. P.
Right arrow Articles by BLOLAND, P. B.
Related Collections
Right arrow Malaria

ADHERENCE TO ANTIMALARIAL COMBINATION THERAPY WITH SULFADOXINE-PYRIMETHAMINE AND ARTESUNATE IN RURAL TANZANIA

S. PATRICK KACHUR, RASHID A. KHATIB, ELLEN KAIZER, SUSAN S. FOX, SALIM M. ABDULLA, AND PETER B. BLOLAND
Malaria Case Management Unit, Malaria Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; Ifakara Health Research and Development Centre, Ifakara, Tanzania; Centers for Disease Control and Prevention Malaria Program in Tanzania, Dar es Salaam, Tanzania

Artemisinin-containing antimalarial combination therapies are recommended to confront drug-resistant Plasmodium falciparum malaria. Among the questions surrounding whether these complex multidose treatments will be practical is to what extent patients complete the recommended doses. Combination therapy through coadministration of sulfadoxine-pyrimethamine plus artesunate was introduced as a first-line treatment for uncomplicated malaria in one district in Tanzania. Interventions to optimize correct use were also implemented. We observed 453 patient encounters at one health facility and recorded key practices as health workers dispensed the combination. A total of 253 patients were followed-up at 24 or 48 hours. Complete adherence measured at 48 hours reached 75.0%, based on self-report and tablet counts. This is substantially better than reported elsewhere and compares favorably with intervention studies to optimize adherence to chloroquine. Counseling about what to do if a patient vomits appears to have been an independent risk factor for nonadherence.


Received January 30, 2004. Accepted for publication June 22, 2004.

Acknowledgments: Ellen Kaizer took part in this project through the International Health Track of the Pediatric Medicine Residency at Rainbow Babies and Children’s Hospital of Case Western Reserve University (Cleveland, OH). Susan S. Fox participated through the epidemiology elective program at the Epidemiology Program Office at CDC. We are grateful to Bernard Mumba and Idd Mkilalu, who served as data collectors, and to the staff and patients at the Ikwiriri Health Centre for their participation in this study. The support of Dr. Hassan Mshinda (Director, Ifakara Health Research and Development Centre) and Dr. Saidi Mkikima (District Medical Officer in Rufiji) is particularly appreciated.

Financial support: This work was supported primarily by the United States Agency for International Development. The particular contributions of Dr. Mary Ettling are appreciated.

Disclaimer: Trade names are used for purposes of identification only and do not constitute endorsement by the United States Public Health Service or the Centers for Disease Control and Prevention.

Author’s addresses: S. Patrick Kachur, Centers for Disease Control and Prevention Malaria Program in Tanzania, PO Box 78373, Dar es Salaam, Tanzania, Telephone: 255-22-213-6689, Fax: 255-22-213-6687, E-mail: skachur{at}cdc.gov. Rashid A. Khatib and Salim M. Abdulla, Ifakara Health Research and Development Centre, Ifakara, Tanzania. Ellen Kaizer and Susan S. Fox, Centers for Disease Control and Prevention Malaria Program in Tanzania, Dar es Salaam, Tanzania. Peter B. Bloland, Malaria Case Management Unit, Malaria Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30341.

* The Interdisciplinary Monitoring Project for Antimalarial Combination Therapy in Tanzania (IMPACT-Tz) is a multiyear implementation research evaluation project that rests on a collaborative platform comprising the United States Centers for Disease Control and Prevention, the Ifakara Health Research and Development Centre, the National Institute for Medical Research, Muhimbili University College of Health Sciences, the London School of Hygiene and Tropical Medicine, and the Tanzanian Ministry of Health, including its National Malaria Control Programme, the Tanzania Essential Health Interventions Project, the Adult Morbidity and Mortality Project, and the Council Health Management Teams of Rufiji, Morogoro, Kilombero, and Ulanga Districts. IMPACT-Tz is primarily supported by funding from the United States Agency for International Development.




This article has been cited by other articles:


Home page
Am J Trop Med HygHome page
L. A. Smith, C. Jones, S. Meek, and J. Webster
Review: Provider Practice and User Behavior Interventions to Improve Prompt and Effective Treatment of Malaria: Do We Know What Works?
Am J Trop Med Hyg, March 1, 2009; 80(3): 326 - 335.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Society of Tropical Medicine and Hygiene.